Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 319 | 58 | 247 |
| Samples | 296 | 54 | 229 |
| Peptides | 226 | 37 | 192 |
Function
RNF103 · Ring finger protein 103
The protein encoded by this gene contains a RING-H2 finger, a motif known to be involved in protein-protein and protein-DNA interactions. This gene is highly expressed in normal cerebellum, but not in the cerebral cortex. The expression of the rat counterpart in the frontal cortex and hippocampus was shown to be induced by elctroconvulsive treatment (ECT) as well as chronic antidepressant treatment, suggesting that this gene may be a molecular target for ECT and antidepressants. The protein is a ubiquitin ligase that functions in the endoplasmic reticulum-associated degradation pathway. Alternative splicing of this gene results in multiple transcript variants. Read-through transcription also exists between this gene and the downstream CHMP3 (charged multivesicular body protein 3) gene. [provided by RefSeq, Oct 2011].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000237455 | O00237 | 319 | 226 |
Gene Properties
Recurrent Mutations
All 226 amino-acid changes on canonical ENST00000237455 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RNF103 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RNF103 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 18/612 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Melanoma | 1/210 0% | 32/1899 2% |
| Colorectal Carcinoma | 6/143 4% | 45/3239 1% |
| Bladder Carcinoma | 1/58 2% | 12/956 1% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 6/810 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 8/752 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Gastric Carcinoma | 3/74 4% | 14/1809 1% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Ovarian Carcinoma | 7/109 6% | 2/998 0% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 10/1390 1% |
| Head and Neck Carcinoma | 1/85 1% | 10/1574 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Non-Cancerous | 0/104 0% | 6/830 1% |
| Ewings Sarcoma | 0/63 0% | 2/262 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Pancreatic Carcinoma | 0/89 0% | 7/1611 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 10/2550 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Other Solid Cancers | 0/94 0% | 5/1515 0% |
| Prostate Carcinoma | 1/13 8% | 5/2105 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 7/2534 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
Mutation Distribution
Where RNF103 is mutated · all tissues, split by cell line vs tissue
How many mutations in RNF103 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 319 mutations in RNF103
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|